Evidence map›Paper›PMID 30213731›Full record

ArticleNeurobiology of disease2018

Assessment of the effects of transthyretin peptide inhibitors in Drosophila models of neuropathic ATTR.

Lorena Saelices, Malgorzata Pokrzywa, Katarzyna Pawelek, David S Eisenberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurobiology of disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Transthyretin amyloid fibrils adopt distinct folds in the brain.bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lorena SaelicesHoward Hughes Medical Institute, UCLA-DOE Institute for Genomics and Proteomics, Department of Biological Chemistry, Molecular Biology Institute, UCLA, 611 Charles Young Dr. East, Los Angeles, 90095, CA, USA. Electronic address: lorenasaelices@mbi.ucla.edu.
Malgorzata PokrzywaAiroptic Sp. z o.o., Ul. Rubiez 46 H, 61-612 Poznań, Poland.
Katarzyna PawelekAiroptic Sp. z o.o., Ul. Rubiez 46 H, 61-612 Poznań, Poland.
David S EisenbergHoward Hughes Medical Institute, UCLA-DOE Institute for Genomics and Proteomics, Department of Biological Chemistry, Molecular Biology Institute, UCLA, 611 Charles Young Dr. East, Los Angeles, 90095, CA, USA.

Funding

Development of inhibitors and diagnostics for amyloid diseasesRF1AG048120 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EISENBERG, DAVID · 2019 to 2019
$1.9M
Development of inhibitors for systemic amyloid diseasesR01AG048120 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EISENBERG, DAVID · 2014 to 2018
$1.9M
NIA NIH HHS R01 AG048120NIA NIH HHS RF1 AG048120
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Amyloid Neuropathies, FamilialAnimalsAnimals, Genetically ModifiedDrosophila melanogasterFemaleHumansPeptide FragmentsPrealbuminRandom AllocationPeptide FragmentsPrealbuminAmyloidosisDrosophilaNeuropathologyPeptide inhibitorsTransthyretin

Identifiers

PMID30213731
PMCPMC6186191

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.